Quantification of Circulating HPV DNA as a Biomarker for Cervical pre-cancer and cancer: A Pilot Study.

Q2 Medicine
Apoorva Gangwar, Shivanjali Raghuvanshi, Shalini Bhalla, Preeti Agarwal, Ajay Kumar Singh, Nisha Singh, Madhu Kumar, Sudhir Singh, Nitu Nigam, Esha Jafa, Harshi Srivastava
{"title":"Quantification of Circulating HPV DNA as a Biomarker for Cervical pre-cancer and cancer: A Pilot Study.","authors":"Apoorva Gangwar, Shivanjali Raghuvanshi, Shalini Bhalla, Preeti Agarwal, Ajay Kumar Singh, Nisha Singh, Madhu Kumar, Sudhir Singh, Nitu Nigam, Esha Jafa, Harshi Srivastava","doi":"10.31557/APJCP.2025.26.5.1681","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Tumor cells release fragments of their DNA into the bloodstream, called cell-free tumor DNA (ctDNA) or liquid biopsy. In this study, we investigate whether human papillomavirus cell-free tumor DNA (ctHPV DNA) can be detected in patients with cervical cancer or premalignant lesions before and after treatment. We are also investigating whether ctHPV DNA levels correlate with patient or tumor characteristics and outcomes.</p><p><strong>Methods: </strong>A total of 67 cases were included, including 42 with locally advanced cervical cancer (LACC) and 11 with early-stage cervical cancer (ESCC), as well as 14 with premalignant lesions. Pre- and post-treatment plasma samples were tested for ctHPV DNA levels using digital droplet PCR.</p><p><strong>Results: </strong>The pretreatment ctHPV DNA was detected in 21.42%(n=09/42) cases with LACC and post treatment ctHPV DNA was detected in 16.66% (07/42) LACC cases. While circulating ctHPV DNA was not detected in ESCC and premalignant lesion cases. Higher levels of ctHPV DNA were correlated to the higher FIGO2018 stage.</p><p><strong>Conclusion: </strong>ctHPV DNA is a promising biomarker in locally advanced cervical cancer and should be further investigated for clinical use. In ESCC patients, the detection rate of ctHPV DNA is not sufficient for clinical benefit even using ddPCR, the most sensitive technologies available.</p>","PeriodicalId":55451,"journal":{"name":"Asian Pacific Journal of Cancer Prevention","volume":"26 5","pages":"1681-1687"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian Pacific Journal of Cancer Prevention","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31557/APJCP.2025.26.5.1681","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Tumor cells release fragments of their DNA into the bloodstream, called cell-free tumor DNA (ctDNA) or liquid biopsy. In this study, we investigate whether human papillomavirus cell-free tumor DNA (ctHPV DNA) can be detected in patients with cervical cancer or premalignant lesions before and after treatment. We are also investigating whether ctHPV DNA levels correlate with patient or tumor characteristics and outcomes.

Methods: A total of 67 cases were included, including 42 with locally advanced cervical cancer (LACC) and 11 with early-stage cervical cancer (ESCC), as well as 14 with premalignant lesions. Pre- and post-treatment plasma samples were tested for ctHPV DNA levels using digital droplet PCR.

Results: The pretreatment ctHPV DNA was detected in 21.42%(n=09/42) cases with LACC and post treatment ctHPV DNA was detected in 16.66% (07/42) LACC cases. While circulating ctHPV DNA was not detected in ESCC and premalignant lesion cases. Higher levels of ctHPV DNA were correlated to the higher FIGO2018 stage.

Conclusion: ctHPV DNA is a promising biomarker in locally advanced cervical cancer and should be further investigated for clinical use. In ESCC patients, the detection rate of ctHPV DNA is not sufficient for clinical benefit even using ddPCR, the most sensitive technologies available.

定量循环HPV DNA作为宫颈癌前期和癌症的生物标志物:一项试点研究。
背景:肿瘤细胞将其DNA片段释放到血液中,称为无细胞肿瘤DNA (ctDNA)或液体活检。在本研究中,我们探讨了人乳头瘤病毒无细胞肿瘤DNA (ctHPV DNA)能否在宫颈癌或癌前病变患者治疗前后检测到。我们还在研究ctHPV DNA水平是否与患者或肿瘤的特征和结果相关。方法:共纳入67例,其中局部晚期宫颈癌(LACC) 42例,早期宫颈癌(ESCC) 11例,癌前病变14例。使用数字液滴PCR检测处理前和处理后血浆样本的ctHPV DNA水平。结果:治疗前21.42%(n=09/42) LACC患者检测到ctHPV DNA,治疗后16.66% (07/42)LACC患者检测到ctHPV DNA。而循环ctHPV DNA未在ESCC和癌前病变中检测到。较高水平的ctHPV DNA与较高的FIGO2018分期相关。结论:ctHPV DNA是一种有前景的局部晚期宫颈癌生物标志物,值得进一步研究用于临床应用。在ESCC患者中,即使使用最灵敏的ddPCR技术,ctHPV DNA的检出率也不足以获得临床效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
2.80
自引率
0.00%
发文量
779
审稿时长
3 months
期刊介绍: Cancer is a very complex disease. While many aspects of carcinoge-nesis and oncogenesis are known, cancer control and prevention at the community level is however still in its infancy. Much more work needs to be done and many more steps need to be taken before effective strategies are developed. The multidisciplinary approaches and efforts to understand and control cancer in an effective and efficient manner, require highly trained scientists in all branches of the cancer sciences, from cellular and molecular aspects to patient care and palliation. The Asia Pacific Organization for Cancer Prevention (APOCP) and its official publication, the Asia Pacific Journal of Cancer Prevention (APJCP), have served the community of cancer scientists very well and intends to continue to serve in this capacity to the best of its abilities. One of the objectives of the APOCP is to provide all relevant and current scientific information on the whole spectrum of cancer sciences. They aim to do this by providing a forum for communication and propagation of original and innovative research findings that have relevance to understanding the etiology, progression, treatment, and survival of patients, through their journal. The APJCP with its distinguished, diverse, and Asia-wide team of editors, reviewers, and readers, ensure the highest standards of research communication within the cancer sciences community across Asia as well as globally. The APJCP publishes original research results under the following categories: -Epidemiology, detection and screening. -Cellular research and bio-markers. -Identification of bio-targets and agents with novel mechanisms of action. -Optimal clinical use of existing anti-cancer agents, including combination therapies. -Radiation and surgery. -Palliative care. -Patient adherence, quality of life, satisfaction. -Health economic evaluations.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信